Josh is Co-Founder of Lux Capital and focuses on investments in the physical and life sciences. Mr. Wolfe manages Lux's investments in Nanosys, Cambrios, Siluria and serves on the Board of Directors of Shapeways, Kymeta, Kurion, and Lux Research. Before forming Lux Capital, he worked in Salomon Smith Barney's Investment Banking group, in capital markets at Merrill Lynch on its Financial Futures & Options/Government Strategy desk and at Prudential Securities in Municipal Finance. Prior to venturing into the financial world, Mr. Wolfe published cutting-edge AIDS-immunopathology research in Cell Vision and The Journal of Leukocyte Biology, leading medical-immunology journals.
Compilation of Josh Wolfe’s Tweetstorms
https://drive.google.com/file/d/1ldRf9JomaRsA_S-g8V6TQPkBOujO5UJ7/view